GM1 Gangliosidosis Treatment Market to Reach US$ 626.86 Million by 2033 as Innovative Therapies Target Lysosomal Storage Disorders

The GM1 gangliosidosis treatment market reached US$ 186.26 million in 2025 and is expected to reach US$ 626.86 million by 2033, growing at a CAGR of 16.6% during the forecast period 2026-2033.

The market is evolving rapidly from a limited supportive-care landscape toward a more innovation-driven therapeutic space focused on addressing the underlying genetic and metabolic mechanisms of GM1 gangliosidosis. Advances in gene therapy, enzyme replacement approaches, substrate reduction strategies, and other emerging treatment modalities are strengthening the development pipeline, while growing awareness, improved diagnosis, and increasing investment in rare-disease research are supporting market expansion. As pharmaceutical and biotechnology companies intensify efforts to develop disease-modifying therapies, the GM1 gangliosidosis treatment landscape is becoming an increasingly important area of rare-disease innovation.

Get a Sample PDF of this Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/gm1-gangliosidosis-treatment-market?ram

United States: Recent Industry Developments

✅ July 2026: Cure GM1 Foundation The foundation reported an FDA INTERACT engagement supporting development of an investigational intracerebroventricular enzyme-replacement strategy for GM1 and continued advancing the program toward an IND. The approach is designed to deliver recombinant β-galactosidase directly into the CNS, potentially bypassing the blood-brain barrier that limits conventional systemic ERT.

✅ May 2026: Cure GM1 Foundation Cure GM1 announced an allocation of up to $1.4 million for the next development phase of its GM1 enzyme-replacement therapy program, substantially expanding its prior investment. The objective is to complete development work required to move ICV ERT toward human clinical testing, creating a treatment modality potentially applicable across GM1 subtypes and ages.

✅ February 2026: National Institutes of Health (NHGRI) Results from the Phase 1/2 AAV9-GLB1 program in Type II GM1 gangliosidosis demonstrated increased CSF β-galactosidase, reduced CSF GM1 ganglioside, and neuroimaging signals consistent with slower cerebral atrophy and improved myelination after a single IV infusion. The nine-patient study provided important clinical validation for systemic AAV-mediated CNS gene delivery while also identifying inflammatory/liver-enzyme safety considerations.

Japan: Recent Industry Developments

✅ August 2026: The Jikei University School of Medicine Researchers provided an updated institutional account of their GM1 gene-therapy program using a transferrin-receptor (TfR)-targeted β-galactosidase strategy. A liver-directed AAV produces the therapeutic enzyme in vivo, enabling BBB transport; treated GM1 mice showed markedly reduced brain substrate accumulation, improved motor performance and extended survival, supporting further human-TfR optimization and safety evaluation.

✅ May 2026: JCR Pharmaceuticals / The Jikei University School of Medicine At ASGCT 2026, the teams presented preclinical AAV9/J-Brain Cargo® data for GM1 gangliosidosis using a TfR antibody-fused β-galactosidase. Intravenous administration produced high circulating enzyme levels and CNS penetration, substantially reducing cerebral GM1 accumulation while improving neurological function and survival in mouse models, with no apparent systemic toxicity.

✅ June 2025: JCR Pharmaceuticals / The Jikei University School of Medicine JCR and Japanese academic collaborators reported establishment of an AAV-based GM1 gene-therapy system expressing a J-Brain Cargo® antibody-fused β-galactosidase, specifically engineered to address BBB limitations. In GM1 mouse models, the treatment produced near-normalization of biochemical/pathological measures and significant behavioral improvement, establishing a preclinical foundation for clinical translation.

Ready to scale in the GM1 Gangliosidosis Treatment Market? Connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/gm1-gangliosidosis-treatment-market?ram

Key Mergers & Acquisitions:

✅ Passage Bio entered into a definitive merger agreement with Remix Therapeutics, Inc. on June 24, 2026. The all-stock transaction is structured as a reverse-merger-style combination in which Passage's wholly owned Peregrine Merger Sub will merge with Remix, with Remix surviving as a wholly owned subsidiary; the combined company is expected to operate as Remix Therapeutics. The transaction included approximately $100 million of concurrent financing and was expected to close in Q4 2026, subject to conditions and shareholder approval. Importantly for the GM1 market, this was not an acquisition of the GM1 program itself: Passage's GM1 economic interests were carved into a CVR structure, with holders entitled to receive their pro-rata share of certain future legacy payments from Gemma under the GM1 license.

✅ Passage Bio gave Gemma Biotherapeutics written notice on May 21, 2026, terminating their broader research, collaboration and license agreement. The agreement covered Gemma's work for Passage on Huntington's disease and temporal-lobe epilepsy plus options for additional CNS programs. The termination did not cancel the separate GM1 sublicense covering PBGM01; the GM1 program remained subject to the previously amended sublicense. This distinction is important because the event represented a strategic unwinding of the broader collaboration rather than a reversal of the GM1 asset transfer.

Key Players:

Passage Bio | Lysogene | Sio Gene Therapies, Inc. | BioStrategies LC | Sanofi | AZAFAROS | Dorphan S.A. | Idorsia Pharmaceuticals Ltd | SphinCS GmbH | Viatris Inc.

Strategic Profiles: How Market Leaders Are Positioning for 2026

-Passage Bio: Advancing gene therapy approaches for GM1 gangliosidosis through its PBGM01 program, which has generated clinical safety and biomarker data in the Imagine-1 study. The company has also pursued strategic partnering to advance its pediatric lysosomal storage disease programs.

-Azafaros: Accelerating development of disease-modifying treatment options through nizubaglustat, an oral small-molecule therapy targeting GM1 and GM2 gangliosidoses. The company completed enrollment in its pivotal Phase 3 GM1/GM2 study in July 2026, positioning the program for further clinical development toward potential treatment of these rare neurological disorders.

-Lysogene: Building its rare-disease positioning around gene therapy and innovative approaches for central nervous system disorders. Its focus on lysosomal storage and neurodegenerative diseases supports continued industry efforts to develop therapies capable of addressing underlying disease mechanisms rather than relying solely on symptomatic management.

-Sio Gene Therapies, Inc.: Strengthening its rare neurological disease strategy through genetic medicine research focused on disorders with significant unmet treatment needs. Its development approach has emphasized gene-based therapeutic technologies designed to address underlying genetic causes of progressive neurological conditions.

-Sanofi: Leveraging its established rare-disease and lysosomal storage disorder capabilities to pursue innovative treatment approaches for gangliosidoses and related conditions. Its substrate-reduction research with venglustat demonstrates continued investment in therapies designed to reduce pathological glycosphingolipid accumulation and address neurological manifestations of rare lysosomal disorders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/gm1-gangliosidosis-treatment-market?ram

GM1 Gangliosidosis Treatment Market Opportunities

-Advancing Gene Therapy: Expanding AAV-based approaches that deliver functional GLB1 genes to restore β-galactosidase activity and address the underlying genetic cause of GM1 gangliosidosis.

-Targeting CNS Disease Progression: Developing therapies capable of delivering treatment effectively to the brain and central nervous system, including intravenous AAV9 approaches and cisterna-magna delivery of investigational vectors such as PBGM01.

-Expanding Disease-Modifying Therapies: Creating opportunities around investigational approaches such as substrate-reduction therapies alongside gene therapy, with clinical research evaluating oral therapies for late-infantile and juvenile GM1 gangliosidosis.

How We Build Trusted Market Research Reports:

Our analysis of the global GM1 Gangliosidosis Treatment Market draws on a blend of primary research including expert interviews and industry surveys and secondary sources such as company filings, clinical trial data, scientific publications, and regulatory records. The report examines the forces shaping the market today, from regulatory developments and treatment advancements to competitive dynamics and historical trends, while also tracking clinical progress, product innovation, and developments in related rare disease therapeutic areas. Beyond current conditions, we assess where the market is headed, mapping growth opportunities, treatment-development challenges, and emerging factors likely to influence its trajectory over the forecast period.

What sets this report apart:

Quarterly updates incorporating the latest clinical, regulatory, M&A, and product-development announcements
Integrated tracking of clinical trials, treatment pipelines, regulatory milestones, and therapeutic developments
Live market-access and industry intelligence via subscription dashboard
Direct analyst customization for client-specific segments or geographies

Regional Insights:

-North America: 42.03% (Largest share, supported by advanced rare-disease research infrastructure, strong clinical-trial networks, orphan-drug incentives, and active gene-therapy development in the U.S.).

-Asia Pacific: 19.4% (Fastest-growing region, driven by expanding genetic screening, improving rare-disease diagnosis, rising healthcare investment, and government support for advanced therapies in China, Japan, and India).

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=gm1-gangliosidosis-treatment-market?ram

Market Segmentation Analysis:

-By Type: GM1 Gangliosidosis Type 1 (Infantile), Type 2 (Juvenile), and Type 3 (Adult), classified based on age of onset and disease progression.

-By Treatment: Enzyme replacement therapy, gene therapy, stem cell transplantation, substrate reduction therapy, pharmacological chaperones, miglustat, N-butyl-deoxynojirimycin (NB-DNJ), and anticonvulsant drugs.

-By End User: Hospitals, ambulatory surgical centers, and other healthcare facilities providing diagnosis, disease management, supportive care, and investigational treatment.

📌 Request for 2 Days FREE Dashboard Access: https://www.datamintelligence.com/reports-subscription?ram

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicated reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.